From September 8th till September 11th the XXXVII Annual Meeting of the European Society for Artificial Organs ESAO was held in Skopje (Macedonia). Organ Assist was represented in Skopje with a special organized lunch symposium. Five specialist were invited by us to present their benefits and experiences with organ preservation.
Author: Willem van Lawick
Herzchirurgie des UKM implantiert erstmalig in Deutschland neuartige Pumpe zur Kurzzeitunterstützung
Münster (ukm/dre). Zum ersten Mal in Deutschland haben Herzchirurgen des Universitätsklinikums Münster (UKM) bei einem Patienten eine neuartige Pumpe für die Kurzzeitunterstützung bei stark pumpschwachen Herzen implantiert. Bei diesem so genannten „PulseCath-System“ wird ein Katheter über die Schlüsselbeinarterie in das Herz vorgeschoben.
Kiadis Pharma receives IND approval from FDA to start pivotal clinical trial with ATIR™
Biopharmaceutical Company Kiadis Pharma announced today that it has received approval for its Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) to start the pivotal clinical study for its product ATIR™ in the United States. Kiadis Pharma is currently enrolling patients in a multinational pivotal clinical study at hospitals in… Continue reading Kiadis Pharma receives IND approval from FDA to start pivotal clinical trial with ATIR™
Prosensa and GlaxoSmithKline initiate development of four additional products under existing alliance in Duchenne Muscular Dystrophy – Broadened program marks key inflexion in Prosensa’s progress to a fully integrated specialty-pharma
Leiden, June 23, 2010 – Prosensa, the Dutch biopharmaceutical company focusing on RNA modulating therapeutics, announces the initiation of two further programmes under its existing alliance with GSK covering novel RNA-based treatments for Duchenne Muscular Dystrophy (DMD). The initiation of these additional programs under the terms of the existing alliance agreement is a validation of… Continue reading Prosensa and GlaxoSmithKline initiate development of four additional products under existing alliance in Duchenne Muscular Dystrophy – Broadened program marks key inflexion in Prosensa’s progress to a fully integrated specialty-pharma
First iVAC3L Case in Greece
The first iVAC3L case in Greece was performed on June 17th, 2010 by Dr. Kyriakos Anastasiadis in Ahepa University Hospital, Thessaloniki. The patient was a male suffering from acute decompensation of chronic heart failure and cardiogenic shock. The patient presented with an ejection fraction of 20% and a cardiac index of 18 L/min/m2.
